
CLAIMS

1. A conjugate having the formula:



wherein M is PEG;

y is a number describing the number of linker-drugs L-D attached to M;

D is selected from the group consisting of rucaparib, talazoparib, and olaparib;

Z* is a carboxamide, carbamate, urea, oxime, thioether, or triazole;

n is 0-6;

R^1 and R^2 are each independently H, CN, or SO_2R^5, wherein wherein R^5 is optionally substituted C_1-C_6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, or $N(R^6)_2$, wherein each R^6 is independently optionally substituted C_1-C_6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, or wherein $N(R^6)_2$ forms a ring of 4-8 atoms;

each R^4 is independently H or C_1-C_3 alkyl or both R^4 groups taken together form a 3-6 membered ring;

Y has the formula $N(R^7)CH_2$, wherein R^7 is optionally substituted C_1-C_4 alkyl or optionally substituted aryl;

and wherein at least one of R^1 and R^2 is other than H.

2. The conjugate of Claim 1 wherein D is rucaparib.

3. The conjugate of Claim 1 wherein D is talazoparib or olaparib.

4. The conjugate of any one of Claims 1-3 wherein M is a PEG of molecular weight between 1,000 and 100,000 Daltons, and y is 1-8.

5. The conjugate of any one of Claims 1-4 wherein M has a hydrodynamic radius between 5 and 50 nm.

6. The conjugate of any one of Claims 1-5 wherein Z* is a 1,2,3-triazole.

7. The conjugate of claim 1, wherein:


a) Z* is a triazole, n is 4, R^1 is $MeSO_2$, R^2 is H, each R^4 is H, R^7 is 2-methoxyethyl, y is 4, and D is talazoparib; or

b) Z* is a triazole, n is 4, R^1 is $MeSO_2$, R^2 is H, each R^4 is H, R^7 is 2-methoxyethyl, y is 4, and D is olaparib; or

c) Z* is a triazole, n is 2, R^1 is $MeSO_2$, R^2 is H, each R^4 is Me, R^7 is 2-methoxyethyl, y is 1, and D is talazoparib;or

d) Z* is a triazole, n is 4, R^1 is $MeSO_2$, R^2 is H, each R^4 is H, R^7 is methyl, y is 1, and D is rucaparib.

8. The conjugate of Claim 1 having the formula:



wherein y is 1, 2, 3, or 4.


9. The conjugate of Claim 8 wherein Z* is a 1,2,3-triazole.

10. The conjugate of claim 8, wherein:

a) Z* is a triazole, n is 4, R^1 is $MeSO_2$, R^2 is H, each R^4 is H, R^7 is 2-methoxyethyl, and y is 4; or

b) Z* is triazole, n is 2, R^1 is $MeSO_2$, R^2 is H, each R^4 is Me, R^7 is 2-methoxyethyl, and y is 1.


11. The conjugate of Claim 1 having the formula:



wherein y is 1, 2, 3, or 4.

12. The conjugate of Claim 1, wherein Z* is a triazole resulting from the cycloaddition of an azide with a cyclooctyne selected from an azadibenzocyclooctyne (DBCO), a bicyclo[6.1.0]non-4-yne (BCN), or 5-hydroxycyclooctyne (5HCO).

13. The conjugate of claim 1, having the formula:



.

14. The conjugate of claim 13, wherein y is 1-8.

15. The conjugate of claim 13, wherein y is 4.

16. Use of a conjugate of any one of Claims 1-15 in the treatment of cancer.